Icon (NASDAQ:ICLR) CAO Emer Lyons Sells 264 Shares of Company Stock

Icon Plc (NASDAQ:ICLR) CAO Emer Lyons sold 264 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $206.66, for a total transaction of $54,558.24. Following the transaction, the chief accounting officer owned 1,217 shares in the company, valued at approximately $251,505.22. The trade was a 17.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Emer Lyons also recently made the following trade(s):

• On Friday, October 23rd, Emer Lyons sold 272 shares of Icon stock. The stock was sold at an average price of $182.37, for a total transaction of $49,604.64.

Icon Price Performance

ICLR opened at $203.77 on Wednesday. Icon Plc has a 1 year low of $66.57 and a 1 year high of $219.04. The company’s 50 day simple moving average is $173.23 and its 200 day simple moving average is $146.72. The stock has a market capitalization of $15.60 billion, a PE ratio of 35.07, a P/E/G ratio of 11.53 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32.

Icon (NASDAQ:ICLR) last issued its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.62 by $0.04. The firm had revenue of $2.02 billion during the quarter, compared to analyst estimates of $2.01 billion. Icon had a net margin of 5.45% and a return on equity of 7.73%. Icon’s revenue for the quarter was down .9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.31 earnings per share. As a group, sell-side analysts expect that Icon Plc will post 9.57 EPS for the current year.

Institutional Trading of Icon

A number of institutional investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. raised its holdings in shares of Icon by 10.3% during the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock valued at $366,481,000 after buying an additional 310,236 shares during the period. Trinity Street Asset Management LLP boosted its holdings in Icon by 27.1% in the 2nd quarter. Trinity Street Asset Management LLP now owns 1,535,462 shares of the medical research company’s stock worth $266,725,000 after acquiring an additional 327,314 shares during the period. Maple Rock Capital Partners Inc. boosted its holdings in Icon by 257.8% in the 2nd quarter. Maple Rock Capital Partners Inc. now owns 1,199,600 shares of the medical research company’s stock worth $208,383,000 after acquiring an additional 864,300 shares during the period. Dimensional Fund Advisors LP boosted its holdings in Icon by 50.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 788,828 shares of the medical research company’s stock worth $87,262,000 after acquiring an additional 265,858 shares during the period. Finally, Sound Shore Management Inc. CT acquired a new stake in Icon in the first quarter valued at approximately $69,379,000. 95.61% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on ICLR. TD Cowen increased their target price on Icon from $197.00 to $254.00 and gave the stock a “buy” rating in a research report on Thursday, October 29th. UBS Group lifted their target price on Icon from $195.00 to $236.00 and gave the company a “neutral” rating in a report on Thursday, October 29th. Jefferies Financial Group reissued a “buy” rating and set a $254.00 price target on shares of Icon in a research report on Thursday, October 29th. Barclays upped their price target on Icon from $175.00 to $230.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 29th. Finally, Truist Financial raised their price objective on Icon from $209.00 to $268.00 and gave the stock a “buy” rating in a report on Thursday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $213.76.

Icon Company Profile

ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.